225 related articles for article (PubMed ID: 38598035)
1. Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors.
Hoogenkamp DS; de Wit-van der Veen LJ; Huizing DMV; Tesselaar MET; van Leeuwaarde RS; Stokkel MPM; Lam MGEH; Braat AJAT
Curr Oncol Rep; 2024 May; 26(5):551-561. PubMed ID: 38598035
[TBL] [Abstract][Full Text] [Related]
2. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.
Adant S; Shah GM; Beauregard JM
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):907-921. PubMed ID: 31492995
[TBL] [Abstract][Full Text] [Related]
3. Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023.
di Santo G; Santo G; Sviridenko A; Virgolini I
Theranostics; 2024; 14(3):940-953. PubMed ID: 38250038
[TBL] [Abstract][Full Text] [Related]
4. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.
van Vliet EI; Teunissen JJ; Kam BL; de Jong M; Krenning EP; Kwekkeboom DJ
Neuroendocrinology; 2013; 97(1):74-85. PubMed ID: 22237390
[TBL] [Abstract][Full Text] [Related]
5. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
Kwekkeboom DJ; Krenning EP
Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
[TBL] [Abstract][Full Text] [Related]
6. Peptide-receptor radionuclide therapy for endocrine tumors.
van Essen M; Krenning EP; Kam BL; de Jong M; Valkema R; Kwekkeboom DJ
Nat Rev Endocrinol; 2009 Jul; 5(7):382-93. PubMed ID: 19488074
[TBL] [Abstract][Full Text] [Related]
7. Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.
Di Franco M; Zanoni L; Fortunati E; Fanti S; Ambrosini V
Curr Oncol Rep; 2024 May; 26(5):538-550. PubMed ID: 38581469
[TBL] [Abstract][Full Text] [Related]
8. External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy.
Das S; Chauhan A; Du L; Thomas KE; Jacob A; Schad A; Jain S; Jessop A; Shah C; Eisner D; Cardin DB; Ciombor KK; Goff LW; Bradshaw M; Delbeke D; Sandler M; Ramirez RA; Berlin J
JAMA Netw Open; 2022 Jan; 5(1):e2144170. PubMed ID: 35044469
[TBL] [Abstract][Full Text] [Related]
9. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Kesavan M; Turner JH
Cancer Biother Radiopharm; 2016 Aug; 31(6):189-98. PubMed ID: 27419665
[TBL] [Abstract][Full Text] [Related]
10. Alpha-emitter Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors.
Bhimaniya S; Shah H; Jacene HA
PET Clin; 2024 Jul; 19(3):341-349. PubMed ID: 38658229
[TBL] [Abstract][Full Text] [Related]
11. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.
Ramage J; Naraev BG; Halfdanarson TR
Semin Oncol; 2018 Aug; 45(4):236-248. PubMed ID: 30539715
[No Abstract] [Full Text] [Related]
12. GEPNETs update: Radionuclide therapy in neuroendocrine tumors.
van der Zwan WA; Bodei L; Mueller-Brand J; de Herder WW; Kvols LK; Kwekkeboom DJ
Eur J Endocrinol; 2015 Jan; 172(1):R1-8. PubMed ID: 25117465
[TBL] [Abstract][Full Text] [Related]
13. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
de Visser M; Verwijnen SM; de Jong M
Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
[TBL] [Abstract][Full Text] [Related]
14. Radionuclide Therapy for Neuroendocrine Tumors.
Cives M; Strosberg J
Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
[TBL] [Abstract][Full Text] [Related]
15. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
[TBL] [Abstract][Full Text] [Related]
17. Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy.
Rabei R; Fidelman N
Curr Treat Options Oncol; 2023 Dec; 24(12):1994-2004. PubMed ID: 38100020
[TBL] [Abstract][Full Text] [Related]
18. Peptide receptor radionuclide therapy of neuroendocrine tumours.
Brabander T; Teunissen JJ; Van Eijck CH; Franssen GJ; Feelders RA; de Herder WW; Kwekkeboom DJ
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):103-14. PubMed ID: 26971847
[TBL] [Abstract][Full Text] [Related]
19. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
[TBL] [Abstract][Full Text] [Related]
20. Additional hepatic
Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
